Johnson & Johnson discontinued two CAR-T programs for large B-cell lymphoma:
CD20 mono CAR-T (JNJ-9530) and CD19/CD20 bispecific CAR-T (JNJ-4496), announced on April 30, 2026.134
Decision based on portfolio priorities and evolving large B-cell lymphoma treatment landscape.137
Programs were in phase 1 and 1/2 trials; J&J acquired them for $245 million in 2023 and projected peak sales over $5 billion.1
Recent data showed 75-80% complete response rates for JNJ-4496, touted as best-in-disease, but no phase 3 advancement.1
J&J will continue supporting enrolled patients per study protocols.13
Sources:
1. https://www.fiercebiotech.com/biotech/jj-axes-5b-car-t-dream-months-after-touting-best-disease-efficacy
3. https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-investigational-programs-in-large-b-cell-lymphoma
4. https://firstwordpharma.com/story/7258095
7. https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/jj-drops-two-lymphoma-car-ts-citing-portfolio-priorities-treatment-landscape-Z56UCNQG4NFAPPINCZQBH37RGQ/